Aclaris Therapeutics (ACRS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$8.2M

Revenue (quarter)

$1.6M

Revenue growth (year over year)

−8.33%

Gross profit (trailing twelve months)

$6.3M

Gross margin

76.08%

Net income (trailing twelve months)

−$75.7M

Net income (quarter)

−$21.5M

Net income growth (year over year)

−39.38%

Net margin

−921.50%

Return on equity

−59.10%

EPS (trailing twelve months)

−$0.58

Book value per share

$0.89

P/E (trailing twelve months)

—

Price to book

3.99

Debt to assets

30.67%

Payout ratio

—

Dividend yield

—

Company profile

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

• Is Aclaris Therapeutics (ACRS) profitable?

  No. Aclaris Therapeutics reported a net loss of $75.7M over the trailing twelve months.

• How much revenue does Aclaris Therapeutics (ACRS) make?

  Aclaris Therapeutics generated $8.2M in revenue over the trailing twelve months, down 8.33% year over year.

• How do I buy stock in Aclaris Therapeutics (ACRS)?

  ACRS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.